Eva Remenar

Budapest, BU 1122, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

Journal: Cancers

Published: March 25, 2022

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

Journal: JCO precision oncology

Published: January 10, 2022

Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC

Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC

Journal: Magyar onkologia

Published: April 18, 2021

Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.

Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 12, 2021

Clinical importance of retropharyngeal lymph node metastases

Clinical importance of retropharyngeal lymph node metastases

Journal: Orvosi hetilap

Published: September 20, 2020

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2019

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Journal: JAMA oncology

Published: November 02, 2018

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 30, 2018

Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology

Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology

Journal: Magyar onkologia

Published: August 10, 2018

Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer

Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer

Journal: Magyar onkologia

Published: June 20, 2018

First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma

First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma

Journal: Magyar onkologia

Published: April 07, 2018

Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.

Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.

Journal: Head & neck

Published: February 28, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026